[1] KUO GAO. 1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and In Silico Target Fishing.[J]. Molecules, 2016, 21 1. DOI:
10.3390/molecules21111600[2] ANA I AHUJA-CASARíN. Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors.[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021: 138-146. DOI:
10.1080/14756366.2020.1847101[3] JULIAN A. CODELLI. Second-Generation Difluorinated Cyclooctynes for Copper-Free Click Chemistry[J]. Journal of the American Chemical Society, 2008, 130 34: 11486-11493. DOI:
10.1021/ja803086r[4] MARIE-JEANNE PAPANDRéOU. The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step.[J]. Molecular Pharmacology, 2002, 61 1 1: 186-193. DOI:
10.1124/mol.61.1.186[5] RAN-JUH WANG Miao L H Chun Hung Yang. 1-Deoxynojirimycin Inhibits Metastasis of B16F10 Melanoma Cells by Attenuating the Activity and Expression of Matrix Metalloproteinases-2 and -9 and Altering Cell Surface Glycosylation[J]. Journal of Agricultural and Food Chemistry, 2010, 58 16: 8988-8993. DOI:
10.1021/jf101401b[6] QINGPU LIU. 1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice.[J]. Molecules, 2015, 20 1: 21700-21714. DOI:
10.3390/molecules201219794